Hutchmed
Hutchmed Limited, commonly referred to as Hutchmed, is a biopharmaceutical company headquartered in Cambridge, UK, with significant operations in China and the United States. Founded in 2016, Hutchmed focuses on the discovery, development, and commercialisation of innovative medicines for the treatment of cancer and autoimmune diseases. The company is renowned for its unique portfolio of targeted therapies, including its flagship product, fruquintinib, which has shown promising results in clinical trials. Hutchmed has established a strong market position, particularly in the Asia-Pacific region, and has achieved notable milestones, such as successful partnerships and regulatory approvals. With a commitment to advancing healthcare, Hutchmed continues to make strides in the biopharmaceutical industry, aiming to improve patient outcomes globally.
DitchCarbon Score
How does Hutchmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hutchmed's score of 27 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hutchmed's reported carbon emissions
In 2023, Hutchmed reported total carbon emissions of approximately 78,772 tonnes CO2e. This figure includes 320 tonnes CO2e from Scope 1 emissions, 6,640 tonnes CO2e from Scope 2 emissions, and a significant 71,812 tonnes CO2e from Scope 3 emissions, which encompasses various categories such as purchased goods and services, employee commute, and business travel. Over the past few years, Hutchmed's emissions have fluctuated, with total emissions recorded at about 5,349 tonnes CO2e in 2020, increasing to approximately 7,551 tonnes CO2e in 2021, and then decreasing to around 5,933 tonnes CO2e in 2022. The company has not set specific reduction targets or initiatives as part of its climate commitments, indicating a need for further development in this area. Hutchmed's emissions data highlights the importance of addressing Scope 3 emissions, which represent the majority of their carbon footprint. The company is positioned within an industry that increasingly prioritises sustainability and climate action, suggesting that future commitments may be necessary to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 672,000 | 0,000,000 | 000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hutchmed is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
